TransCon PTH 治疗成人甲状旁腺功能减退症的疗效与安全性:3 期 PaTHway 试验 52 周结果
PaTHway 3 期试验纳入 82 例成人甲状旁腺功能减退症患者,开放扩展期所有受试者接受每日一次 TransCon PTH(palopegteriparatide)。第 52 周时 81%(63/78)达到多组分疗效终点,95%(74/78)摆脱常规治疗,24 小时尿钙从基线 376 mg/天降至 195 mg/天,安全性和耐受性良好。
要点
- 第 52 周 81%(63/78)达到血糖正常且摆脱常规治疗的多组分终点。
- 95%(74/78)摆脱常规治疗,无人需要活性维生素 D。
- 24 小时尿钙从基线 376 mg/天降至第 52 周 195 mg/天。
核心结论
- PaTHway 试验第 52 周时,TransCon PTH 在成人甲状旁腺功能减退症患者中显示出持续疗效、安全性和耐受性。
研究设计与样本
- 3 期试验,包括 26 周双盲、安慰剂对照期,随后为 156 周开放标签扩展期(OLE)。
- 在北美和欧洲的 21 个中心进行。
- 82 例成人甲状旁腺功能减退症患者被随机分组并接受研究药物,78 例完成第 52 周。
- 所有 OLE 参与者接受每日一次 TransCon PTH 给药。
主要发现
- 第 52 周时,81%(63/78)达到多组分疗效终点,即血清钙正常(8.3-10.6 mg/dL)且摆脱常规治疗(元素钙≤600 mg/天且无活性维生素 D)。
- 第 52 周时,95%(74/78)实现摆脱常规治疗,无人需要活性维生素 D。
- 患者报告结局显示生活质量、身体功能和幸福感持续改善。
- 从基线至第 52 周,骨密度 Z 均值向年龄和性别匹配的正常值下降。
- 24 小时尿钙排泄均值(SD)从基线 376(168)mg/天降至第 52 周 195(114)mg/天。
关键数值与推荐
- 多组分疗效终点:第 52 周血清钙正常(8.3-10.6 mg/dL)且摆脱常规治疗(元素钙≤600 mg/天且无活性维生素 D)。
- 第 52 周达到多组分疗效终点比例为 81%(63/78)。
- 第 52 周摆脱常规治疗比例为 95%(74/78)。
- 24 小时尿钙排泄均值(SD)从基线 376(168)mg/天降至第 52 周 195(114)mg/天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Conventional therapy for hypoparathyroidism aims to alleviate symptoms of hypocalcemia but does not address insufficient parathyroid hormone (PTH) levels. OBJECTIVE: Assess the long-term efficacy and safety of TransCon PTH (palopegteriparatide) for hypoparathyroidism. DESIGN: Phase 3 trial with a 26-week, double-blind, placebo-controlled period followed by a 156-week, open-label extension (OLE). SETTING: Twenty-one sites across North America and Europe. PARTICIPANTS: A total of 82 adults with hypoparathyroidism were randomized and received study drug and 78 completed week 52. INTERVENTION(S): All OLE participants received TransCon PTH administered once daily. MAIN OUTCOME MEASURE(S): Multicomponent efficacy endpoint: proportion of participants at week 52 who achieved normal serum calcium (8.3-10.6 mg/dL) and independence from conventional therapy (≤600 mg/day of elemental calcium and no active vitamin D). Other efficacy endpoints included patient-reported outcomes and bone mineral density. Safety was assessed by 24-hour urine calcium and treatment-emergent adverse events. RESULTS: At week 52, 81% (63/78) met the multicomponent efficacy endpoint, 95% (74/78) achieved independence from conventional therapy, and none required active vitamin D. Patient-reported outcomes showed sustained improvements in quality of life, physical functioning, and well-being. Mean bone mineral density Z-scores decreased toward age- and sex-matched norms from baseline to week 52. Mean (SD) 24-hour urine calcium excretion decreased from 376 (168) mg/day at baseline to 195 (114) mg/day at week 52. Most treatment-emergent adverse events were mild or moderate and none led to trial discontinuation during the OLE. CONCLUSION: At week 52 of the PaTHway trial, TransCon PTH showed sustained efficacy, safety, and tolerability in adults with hypoparathyroidism.
引用
- Clarke BL, Khan AA, Rubin MR, et al. Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. J Clin Endocrinol Metab. 2025. PMID: 39376010. doi:10.1210/clinem/dgae693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。